Rebastinib attenuates acute lung injury by promoting NLRP3 ubiquitination and blocking NLRP3/GSDMD signaling pathway in macrophages and protecting alveolar epithelial cells.

Summary: Acute lung injury is a very serious lung disease that makes it hard to breathe. Right now, there are no good treatments for it. Scientists tested a cancer drug called Rebastinib to see if it could help. They found that Rebastinib stops a chain reaction in the body that causes swelling and cell death in the lungs. In tests with mice and cells, the drug protected the lungs and reduced damage. This means Rebastinib could be a promising new treatment to help people with this dangerous lung disease.